Munck Wilson Opens Fort Worth Life Sciences Push
Decision brief
Answer first · skim in under a minute
Dallas-based Munck Wilson Mandala opened a Fort Worth office under partner Quintin Cassady, a longtime life sciences general counsel formerly at Galderma Laboratories and Modern Meadow. The move targets North Texas biotech, medtech, and manufacturing clients that often send complex work to larger coastal firms.
Dallas-based Munck Wilson Mandala opened a Fort Worth office under partner Quintin Cassady, a longtime life sciences general counsel formerly at Galderma Laboratories and Modern Meadow. The move targets North Texas biotech, medtech, and manufacturing clients that often send complex work to larger coastal firms.
Contents10 sections
Key Takeaways
- Munck Wilson Mandala launched a Fort Worth office led by Quintin Cassady, emphasizing life sciences and technology clients.
- Cassady’s background includes in-house leadership at Galderma Laboratories in Fort Worth and biotech company Modern Meadow.
- Texas remains a dense trial and manufacturing geography, visible in ClinicalTrials.gov registrations and FDA-regulated site activity.
- Firm expansion claims about partner headcount targets are management aspirations, not regulator-verified forecasts.
What changed in Fort Worth’s life sciences legal market?
Munck Wilson Mandala planted a Fort Worth flag with Cassady as the local lead after decades of Dallas-centric coverage of the metroplex. The firm positions the office for complex transactions, intellectual property strategy, and disputes for growth-stage companies.
Cassady’s Galderma tenure matters because Fort Worth already hosts substantial dermatology and consumer health manufacturing. Clients often need counsel who understand both FDA-facing operations and Texas commercial practice.
Why does North Texas show up in national trial data?
Sponsors routinely site interventional studies across Texas academic and community networks. ClinicalTrials.gov Texas listings illustrate the volume of registered research that creates contracting, IP, and compliance work for local counsel.
That trial density is one reason life sciences firms expand beyond Austin and Houston into Fort Worth’s corporate base. Legal demand follows investigational sites, manufacturing plants, and headquarters moves—not the other way around.
How do FDA manufacturing rules shape counsel needs?
Companies scaling sterile or solid-oral capacity in Texas must navigate current good manufacturing practice expectations summarized across FDA CGMP resources.
Galderma-era and biotech GC experience is relevant when boards ask whether Fort Worth operations can support inspections, tech transfer, and recall readiness without defaulting every matter to New York or California counsel.
What capital-markets context surrounds Texas biotech growth?
Public biotech issuers still disclose material pipeline and facility risks through SEC filings searchable on SEC EDGAR. Local counsel supporting financings need fluency in those disclosure patterns even when the listing exchange is elsewhere.
Office openings do not change listing rules. They do change which partner sits across the table when a Fort Worth manufacturer prepares an IND-enabling tech-transfer schedule or a Series B data room.
What should clients ask before switching counsel?
Ask for recent FDA inspection support, Hatch-Waxman or biosimilar dispute experience, and how conflicts are cleared across Texas offices. Confirm whether life sciences partners will staff trials contracting versus only corporate M&A.
- Map which matters stay local versus Dallas overflow.
- Request sample engagement letters for clinical site agreements.
- Clarify AI/IP bench depth if software-enabled devices are in scope.
What remains unproven?
Partner hiring targets such as six to eight lawyers by year-end are business plans reported in secondary interviews, not audited metrics. NovaPharma News could not locate an allowlisted wire copy of the firm press release at enrichment time.
Treat the Fort Worth launch as a market-structure signal: more onshore life sciences legal capacity near manufacturing and trial sites. Do not treat it as a predictor of any single company’s FDA timeline.
Related NovaPharma coverage
- Healthcare packaging supply-chain expansion coverage
- FDA OTC naloxone access update
- Biotech capital efficiency analysis
Frequently Asked Questions
Who is leading Munck Wilson’s Fort Worth office?
Partner Quintin Cassady, a former Galderma Laboratories and Modern Meadow general counsel with deep Fort Worth ties, is leading the new office.
Why does this matter for pharma companies?
North Texas hosts manufacturing and clinical research activity that needs local FDA-aware counsel for contracting, IP, and compliance matters.
Is the office expansion verified by a regulator?
No. It is a private law-firm business decision. Regulatory sources cited here describe the broader Texas trial and CGMP context, not the firm’s lease.
Primary Sources
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
